CEN Biotech, Inc.
CENBF
$0.0001
$0.000.00%
| Weiss Ratings | CENBF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Unrated | |||
| Risk Index | Unrated | |||
| Risk Grade | U | |||
| Reward Grade | U | |||
| Rating Factors | CENBF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Unrated | |||
| Growth Index | Unrated | |||
| Efficiency Index | Unrated | |||
| Solvency Index | Unrated | |||
| Total Return Index | Unrated | |||
| Volatility Index | Unrated | |||
| Beta / Standard Deviation | CENBF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -155.74 | |||
| Price History | CENBF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -- | |||
| 30-Day Total Return | -- | |||
| 60-Day Total Return | -- | |||
| 90-Day Total Return | 0.00% | |||
| Year to Date Total Return | -- | |||
| 1-Year Total Return | -97.73% | |||
| 2-Year Total Return | -99.33% | |||
| 3-Year Total Return | -99.90% | |||
| 5-Year Total Return | -100.00% | |||
| 52-Week High % Change | -99.33% | |||
| 52-Week Low % Change | 9,900.00% | |||
| Price | CENBF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.01 | |||
| 52-Week Low Price | $0.00 | |||
| 52-Week Low Price (Date) | Jul 09, 2024 | |||
| 52-Week High Price (Date) | Mar 14, 2024 | |||
| Valuation | CENBF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 6.53K | |||
| Enterprise Value | -- | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.06 | |||
| Earnings Per Share Growth | 194.12% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.00 | |||
| Price/Book (Q) | 0.00 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.00 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -- | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | CENBF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 63.99M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | CENBF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | -- | |||
| Address | 3295 Quality Way Windsor, ON N8T 3R9 | |||
| Website | www.cenbiotechinc.com | |||
| Country | Canada | |||
| Year Founded | 2013 | |||
| Profitability | CENBF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -94.55% | |||
| Profit Margin | -223.96% | |||
| Management Effectiveness | CENBF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -9.95% | |||
| Return on Equity | -- | |||
| Income Statement | CENBF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 1.37M | |||
| Total Revenue (TTM) | 1.37M | |||
| Revenue Per Share | $0.02 | |||
| Gross Profit (TTM) | 1.37M | |||
| EBITDA (TTM) | -870.90K | |||
| EBIT (TTM) | -1.30M | |||
| Net Income (TTM) | -3.08M | |||
| Net Income Avl. to Common (TTM) | -3.08M | |||
| Total Revenue Growth (Q YOY) | -50.07% | |||
| Earnings Growth (Q YOY) | 44.33% | |||
| EPS Diluted (TTM) | -0.06 | |||
| EPS Diluted Growth (Q YOY) | 58.55% | |||
| Balance Sheet | CENBF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 148.20K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 300.50K | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -2.11M | |||
| Current Ratio (Q) | 0.031 | |||
| Book Value Per Share (Q) | -$0.03 | |||
| Total Assets (Q) | 7.91M | |||
| Total Current Liabilities (Q) | 9.83M | |||
| Total Debt (Q) | 5.62M | |||
| Total Liabilities (Q) | 10.02M | |||
| Total Common Equity (Q) | -2.11M | |||
| Cash Flow | CENBF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -56.80K | |||
| Cash from Financing (TTM) | 576.50K | |||
| Net Change in Cash (TTM) | -65.40K | |||
| Levered Free Cash Flow (TTM) | -45.10K | |||
| Cash from Operations (TTM) | -590.70K | |||
